Fundraising Fox
/Companies
Sign in

Transplant Genomics

Brookline, US · Founded 2013 · Delaware corporation

Find your way into Transplant Genomics

Sign up to see every warm intro you have to Transplant Genomics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Transplant Genomics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Transplant Genomics develops non-invasive molecular diagnostic tests to detect early signs of graft rejection and injury in kidney and liver transplant patients, helping clinicians optimize immunosuppressive therapy and avoid painful biopsies. The company serves transplant centers and clinicians worldwide.

BiotechDigital HealthMedical Devices

Founders & leadership

KHKyle Hart
Kyle HartVice President of Informatics2015–2016Kyle Hart has held product and technical leadership roles in clinical software development, including work on diagnostic testing programs, health data integration systems, and genomics applications. His background spans product management, system architecture, and biomarker development across healthcare and life sciences organizations.
DLDarren Lee
Darren LeeVice President - Marketing & Reimbursement2015–2020
DP
Dierdre PierryExecutive
SR
Stanley RoseExecutive
RF
Roy FirstExecutive
BJ
Brett JensenVice President of Sales2014–2016Brett Jensen is Executive Officer at Transplant Genomics, which develops non-invasive molecular diagnostic tests to detect early signs of graft rejection in transplant patients. He brings over 25 years of experience in healthcare sales, marketing, and business development across multiple functions.
MA
Michael AbecassisNamed on SEC filing
DS
Daniel SalomonNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$20.6M disclosed across 7 rounds · 2014–2018

▶$8MraisedSep 2018 · 31 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Darren LeeExecutive Officer
  • Stanley RoseExecutive Officer, Director
  • Roy FirstExecutive Officer
  • Jay VenkatesanDirector
  • David KravitzDirector
  • Chris O'ConnorDirector
  • Michael AbecassisDirector
  • Peter LewisExecutive Officer
Offering amount
$8M
Amount sold
$8M
Sales commissions
$200K
First sale
Aug 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedApr 2017 · 27 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Jay VenkatesanDirector
  • Michael AbecassisDirector
  • Chris O'ConnorDirector
  • Stanley RoseExecutive Officer, Director
  • Darren LeeExecutive Officer
  • Peter LewisExecutive Officer
  • Roy FirstExecutive Officer
Offering amount
$5.5M
Amount sold
$3.2M
Finders' fees
$31.5K
Placement agents
Arcadia Securities, LLC
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedFeb 2017 · 22 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Darren LeeExecutive Officer
  • Michael AbecassisDirector
  • Peter LewisExecutive Officer
  • Roy FirstExecutive Officer
  • Stanley RoseExecutive Officer, Director
Offering amount
$3.5M
Amount sold
$1.7M
Finders' fees
$21.7K
Placement agents
Arcadia Securities, LLC
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$530KraisedMay 2016 · 8 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy FirstExecutive Officer
  • Dierdre PierryExecutive Officer
  • Brett JensenExecutive Officer
  • Michael AbecassisDirector
  • Stanley RoseExecutive Officer, Director
  • Kyle HartExecutive Officer
  • Daniel SalomonDirector
  • Darren LeeExecutive Officer
Offering amount
$1M
Amount sold
$530K
First sale
Apr 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedOct 2015 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kyle HartExecutive Officer
  • Darren LeeExecutive Officer
  • Michael AbecassisDirector
  • Dierdre PierryExecutive Officer
  • Stanley RoseExecutive Officer, Director
  • Daniel SalomonDirector
  • Roy FirstExecutive Officer
  • Brett JensenExecutive Officer
Offering amount
$3M
Amount sold
$1.2M
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedMay 2015 · 47 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel SolomonDirector
  • Michael AbecassisDirector
  • Stanley RoseExecutive Officer, Director
Offering amount
$3.2M
Amount sold
$3.2M
Minimum investment
$6.3K
First sale
Nov 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedApr 2014 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stanley RoseExecutive Officer, Director
  • Michael AbecassisDirector
  • Daniel SalomonDirector
Offering amount
$3M
Amount sold
$2.8M
Minimum investment
$5K
First sale
Mar 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
05, 06b, 4a5
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

UPMCUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
CareDxCareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.

Companies working in the same space as Transplant Genomics.

Frequently asked questions

What does Transplant Genomics do?
Transplant Genomics develops non-invasive molecular diagnostic tests to detect early signs of graft rejection and injury in kidney and liver transplant patients, helping clinicians optimize immunosuppressive therapy and avoid painful biopsies. The company serves transplant centers and clinicians worldwide.
How much funding has Transplant Genomics raised?
Transplant Genomics has disclosed $20.6M raised across 7 rounds.
Where is Transplant Genomics headquartered?
Transplant Genomics is headquartered in Brookline, US.